Multiple sclerosis

Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021

Friday, September 24, 2021 - 5:51pm

LONDON, Sept. 24, 2021 (GLOBE NEWSWIRE) -- London, 24 September 2021 Tiziana Life Sciences plc (Tiziana, LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2021.

Key Points: 
  • LONDON, Sept. 24, 2021 (GLOBE NEWSWIRE) -- London, 24 September 2021 Tiziana Life Sciences plc (Tiziana, LSE: TILS, NASDAQ: TLSA), a biotechnology company a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2021.
  • Furthermore these pharmacodynamic data point to a clinical dose range that Tiziana intends to test in further clinical development among MS patients.
  • For the six months to 30 June 2020 the consolidated Group made a loss of 12.59m (six months to 30 June 2020: 3.9m).
  • The Group ended the period with 38.6m cash as at 30 June 2021 (31 December 2020: 48.2m).

GeNeuro and Northwestern University Enter Into a Research Collaboration on HERV-W ENV in Long-haul COVID

Friday, September 24, 2021 - 2:00pm

Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.

Key Points: 
  • Northwestern University is a pioneer in the comprehensive treatment of long-haul COVID-19 symptomatology, having established a Neuro COVID-19 Clinic at Northwestern Memorial Hospital as early as May 2020.
  • The purpose of the research agreement is to establish evidence of W-ENV expression on the transcriptional and protein level, to ascertain whether this protein can be a blood biomarker of neurological complications of long-haul COVID.
  • This research agreement complements the previously announced efforts in the long-haul COVID field that GeNeuro has launched in Europe with Fondation FondaMental and the CIRI (International Center for Infectiology Research, Lyon, France).
  • GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France.

TG Therapeutics Announces Publication of Results from an Integrated Safety Analysis of UKONIQ® (umbralisib) in Blood Advances

Thursday, September 23, 2021 - 1:00pm

Michael S. Weiss, the Companys Chairman and Chief Executive Officer stated, We are pleased that the integrated safety analysis of 371 patients treated with UKONIQ has been published in Blood Advances.

Key Points: 
  • Michael S. Weiss, the Companys Chairman and Chief Executive Officer stated, We are pleased that the integrated safety analysis of 371 patients treated with UKONIQ has been published in Blood Advances.
  • The integrated safety data analysis of umbralisib published [today/yesterday] is encouraging for patients, especially given the low rate of discontinuations due to adverse events observed.
  • These data are described further in the manuscript entitled, Integrated safety analysis of umbralisib, a dual PI3K/CK1 inhibitor, in relapsed/refractory lymphoid malignancies, which was published online in Blood Advances.
  • UKONIQ is a trademark ofTG Therapeutics, Inc.
    UKONIQ is the first and onlyoral inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1(CK1) epsilon.

TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Thursday, September 23, 2021 - 12:30pm

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Healthcare Conference, taking place September 27 30, 2021.

Key Points: 
  • NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Companys Chairman and Chief Executive Officer, will participate in a fireside chat during the 2021 Cantor Virtual Healthcare Conference, taking place September 27 30, 2021.
  • The fireside chat is scheduled to take place on Monday, September 27, 2021 at 10:40 AM ET.
  • TG Therapeuticsis a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • UKONIQ is a registered trademark of TG Therapeutics, Inc.

MPM Strengthens its Team with the Addition of Accomplished Biotech Executive and Drug Discoverer Wendy Young, PhD

Thursday, September 23, 2021 - 1:44pm

MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive and drug discoverer Wendy Young, PhD, to its team of accomplished Executive Partners.

Key Points: 
  • MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive and drug discoverer Wendy Young, PhD, to its team of accomplished Executive Partners.
  • At Genentech, Wendy led research activities and oversaw 900 internal and external multi-disciplinary scientists engaged in drug discovery.
  • Earlier in her career, Wendy held drug discovery roles at SCIOS, a Johnson & Johnson Company, and Celera Genomics.
  • Were delighted that Wendy has joined our senior team of MPM Entrepreneurs, said Ed Hurwitz, Managing Director, MPM Capital.

Eaze Launches Statewide Program To Bring Free Medical Cannabis to Low-Income Patients

Thursday, September 23, 2021 - 2:00pm

Eaze Compassion bridges the “last mile” between low-income patients and the products they need to survive and thrive. Utilizing Eaze’s statewide network of brands and delivery drivers, Eaze Compassion aggregates donated products and then -- working with leading compassion organizations including Weed For Warriors, Operation Evac, This Is Jane Project and Brownie Mary Democratic Club -- identifies patients shut out from the legal market by high taxes or residency in the 70% of California jurisdictions where legal cannabis commerce is banned.

Key Points: 
  • Eaze , the nations largest cannabis delivery marketplace, today celebrated the launch of Eaze Compassion, a statewide program to restore medical cannabis access to patients left behind by Californias cannabis laws.
  • Eligibility is determined and verified by Eaze Compassions partner organizations based on criteria including income, medical diagnosis, and need.
  • Interested patients can contact Operation Evac , Weed for Warriors , This is Jane Project , Bay Area Americans for Safe Access and Dear Cannabis for information on Eaze Compassion eligibility.
  • Under Prop 215, medical providers could donate cannabis free of charge to low income patients.

Aruna Bio Appoints John Richard to Board of Directors

Thursday, September 23, 2021 - 2:00pm

ATHENS, Ga. and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 /PRNewswire/ -- Aruna Bio, Inc. , a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced the addition of John Richard to its Board of Directors.

Key Points: 
  • ATHENS, Ga. and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 /PRNewswire/ -- Aruna Bio, Inc. , a leader in the development of neural exosome based therapeutics for the treatment of neurodegenerative diseases, today announced the addition of John Richard to its Board of Directors.
  • Mr. Richard joins the Aruna Bio Board of Directors with over thirty-five years of experience in biopharmaceuticals and life science investments.
  • "We are very pleased to have John join our Board of Directors adding further depth to our pharmaceutical/biotech expertise," said Bill Griffin, Chairman of Aruna Bio.
  • John Richard is Co-Founder and Chief Business Officer for Mereo BioPharma plc, a publicly traded biopharmaceutical company founded in 2015.

Helius Medical Technologies, Inc. to Present at the Benzinga Healthcare Small Cap Conference

Wednesday, September 22, 2021 - 9:05pm

Helius Medical Technologies is a neurotech company focused on neurological wellness.

Key Points: 
  • Helius Medical Technologies is a neurotech company focused on neurological wellness.
  • The Companys purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brains ability to heal itself.
  • The Companys first commercial product is the Portable Neuromodulation Stimulator (PoNS).
  • The PoNS is an investigational medical device in the Australia (AUS) and is currently under premarket review by the AUS Therapeutic Goods Administration.

Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points

Wednesday, September 22, 2021 - 12:30pm

These new results suggest that the hearing of individuals administered with a single dose of FX-322 may improve over extended periods.

Key Points: 
  • These new results suggest that the hearing of individuals administered with a single dose of FX-322 may improve over extended periods.
  • We also plan to assess individuals treated in our other studies to evaluate if those subjects may have experienced these longer-term benefits.
  • Hearing function was tested in 32 subjects (one subject did not finish the study) over the course of 90 days following dosing.
  • Subjects in the study had an array of hearing loss etiologies, including sudden SNHL, noise-induced SNHL and idiopathic SNHL.

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Wednesday, September 22, 2021 - 11:30am

In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.

Key Points: 
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • We were very pleased with this license agreement with Immunic and look forward to future results with these very promising combinations."
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.